drugset

drugset / Trial / NCT03460457

Tolerance and Pharmacokinetics of TQB2450

NCT03460457 ↗

Phase 1 Unknown 50 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To study the pharmacokinetic characteristics of TQB2450 in the human body, recommend a reasonable regimen for subsequent research.

Timeline

Start: 2018-03-15
Primary completion: 2019-03-15
Completion: 2019-03-15

Publications

Xue J, Xue L, Tang W, Ge X, Zhao W, Li Q, Peng W, Dai C, Guo Y, Li J. TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study. Ther Adv Med Oncol. 2024 Jan 6;16:17588359231220516. doi: 10.1177/17588359231220516. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Benmelstobart	Monoclonal antibody	1200 mg	Intravenous

Indications